Skip to main content
. 2019 Dec 17;7:411. doi: 10.3389/fbioe.2019.00411

Figure 6.

Figure 6

Testing disease-modifying effects of Celecoxib in iPSC-derived OC chip-based OA model. (A) Schematic of treatments. After the formation of OC tissue, IL-1β was used to generate “OA” model (OA group). Administration of Celecoxib to both cartilage and bone components of OC chip simulated systemic treatment (SY group), while administration tocartilage alone simulated intraarticular treatment (IA group). Normal OC tissues without any treatment served as the control (CL). (B) Expression levels of catabolic genes in the cartilage part of OC and CH constructs. All data are normalized to RPL13A. N = 4 per group; *p < 0.05; **p < 0.01; ***p < 0.001; ****p< 0.0001. (C) Expression levels of IL-1β, IL-6, and OCN in the bone side of OC tissue. All data are normalized to RPL13A. N = 4 per group. *p < 0.05; **p < 0.01. (D) Alcian Blue (top) and Alizarin Red (bottom) staining of samples from OC constructs with different treatments. Bar = 200 μm.